Nichi-Iko Pharmaceutical to Buy Sagent in $736 Million Cash Deal

  • Bid represents 40 percent premium of over last closing price
  • Establishes toehold in U.S. market amid expansion plans

Nichi-Iko Pharmaceutical Co. agreed to buy Sagent Pharmaceuticals Inc. for $736 million in cash, allowing the Japanese company to build its presence in the U.S. market as it looks to become one of the world’s top manufacturers of generic medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.